(Q36554418)

14 August 2017

1 reference

title

Strategies for optimizing combinations of molecularly targeted anticancer agents (English)

1 reference

14 August 2017

Janet E Dancey

1

1 reference

PubMed ID

16883303

14 August 2017

Helen X Chen

series ordinal

2

1 reference

14 August 2017

1 August 2006

1 reference

Nature Reviews Drug Discovery

14 August 2017

1 reference

14 August 2017

5

1 reference

14 August 2017

649-659

1 reference

14 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2089

14 August 2017

0 references

cites work

Radiation therapy and tamoxifen: concurrent or sequential? That is the question

1 reference

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab

31 March 2020

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

31 March 2020

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

31 March 2020

1 reference

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

31 March 2020

1 reference

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

31 March 2020

1 reference

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

31 March 2020

1 reference

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada [...]

31 March 2020

1 reference

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

31 March 2020

1 reference

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

31 March 2020

1 reference

Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196

31 March 2020

1 reference

Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens

31 March 2020

1 reference

Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.

31 March 2020

1 reference

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

31 March 2020

1 reference

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

31 March 2020

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy

31 March 2020

1 reference

A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).

31 March 2020

1 reference

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

31 March 2020

1 reference

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

31 March 2020

1 reference

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

31 March 2020

1 reference

Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fr

31 March 2020

1 reference

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

31 March 2020

1 reference

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

31 March 2020

1 reference

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

31 March 2020

1 reference

ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study

31 March 2020

1 reference

Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development

31 March 2020

1 reference

Drug combinations: from laboratory to practice

31 March 2020

1 reference

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

31 March 2020

1 reference

Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures

31 March 2020

1 reference

Genetic instability of cell lines derived from a single human small cell carcinoma of the lung

31 March 2020

1 reference

Sequential cytogenetic studies in an ovarian cancer cell line

31 March 2020

1 reference

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

31 March 2020

1 reference

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

31 March 2020

1 reference

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

31 March 2020

1 reference

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

31 March 2020

1 reference

The concept of synthetic lethality in the context of anticancer therapy

31 March 2020

1 reference

Systematic discovery of multicomponent therapeutics

31 March 2020

1 reference

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

31 March 2020

1 reference

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2089

1 reference

14 August 2017

1 reference

PubMed ID

16883303